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Abstract The blood-brain barrier (BBB) is formed by the endothelial cells lining cerebral
microvessels, but how blood-borne signaling molecules influence permeability is incompletely
understood. We here examined how the apolipoprotein M (apoM)-bound sphingosine 1–phosphate
(S1P) signaling pathway affects the BBB in different categories of cerebral microvessels using
ApoM deficient mice (Apom-/-). We used two-photon microscopy to monitor BBB permeability of
sodium fluorescein (376 Da), Alexa Fluor (643 Da), and fluorescent albumin (45 kDA). We show that
BBB permeability to small molecules increases in Apom-/- mice. Vesicle-mediated transfer of
albumin in arterioles increased 3 to 10-fold in Apom-/- mice, whereas transcytosis in capillaries and
venules remained unchanged. The S1P receptor 1 agonist SEW2871 rapidly normalized paracellular
BBB permeability in Apom-/- mice, and inhibited transcytosis in penetrating arterioles, but not in
pial arterioles. Thus, apoM-bound S1P maintains low paracellular BBB permeability in all cerebral
microvessels and low levels of vesicle-mediated transport in penetrating arterioles.
Introduction
The blood-brain barrier (BBB) allows only certain molecules and cells to pass from the blood circula-
tion to the brain. Molecules cross the BBB via the paracellular route by diffusion between endothelial
cells (Tietz and Engelhardt, 2015), or by transcellular route, including vesicular transport across the
endothelium (De Bock et al., 2016). The selectivity of the BBB towards small molecules is main-
tained by tight and adherens junctions between adjoining endothelial cells (Tietz and Engelhardt,
2015), whereas the transport of large molecules is restricted by receptor-mediated interactions
(De Bock et al., 2016). Under normal conditions, the BBB maintains low permeability due to the
structural barrier maintained by junctional complexes and the low rate of transcytosis (De Bock
et al., 2016; Daneman and Prat, 2015; Nico and Ribatti, 2012; Abbott et al., 2010). In disease
states, the loss of BBB function leads to increased permeability, which is viewed mainly as the conse-
quence of disrupted junctional complexes at endothelial cell contact sites (Davies, 2002;
Engelhardt et al., 2014; Salameh et al., 2016). However, recent evidence suggests equal impor-
tance of transcytosis, as a failure in the homeostatic regulation of endothelial trans-cellular transport
may aggravate brain pathologies (Knowland et al., 2014; Habgood et al., 2007; Hashizume and
Black, 2002; Krueger et al., 2013).
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid synthesized by all mammalian cells,
with blood-circulating S1P produced by vascular endothelial cells, platelets, and erythrocytes
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(Thuy et al., 2014; Blaho and Hla, 2014; Xiong and Hla, 2014; Prager et al., 2015). S1P is a ligand
for five membrane-bound G-protein-coupled receptors (S1PR1-5), and the brain endothelium
expresses S1PR1-3 (Prager et al., 2015). The majority (~70%) of S1P in the blood circulation is trans-
ported by apolipoprotein M (apoM), a 26 kDa protein mainly associated with high-density lipopro-
tein (HDL) (Xu and Dahlba¨ck, 1999), while the remaining S1P fraction is carried primarily by albumin
(Ruiz et al., 2017; Christoffersen et al., 2011).
Depending on the carrier (i.e., apoM or albumin), S1P preferentially activates S1PR1 or S1PR2
and S1PR3, which can exert opposite effects (Murata et al., 2000). For example, S1PR1 stimulation
inhibits neuroinflammation, whereas S1PR2 and S1PR3 stimulation facilitates pro-inflammatory sig-
naling cascades (Sanchez et al., 2007; Sanchez, 2016; Blaho et al., 2015). The onset and severity
of sepsis in humans correlate with reduced apoM-S1P plasma concentrations and loss of BBB integ-
rity (Davies, 2002; Kumaraswamy et al., 2012). In mice, lack of apoM compromises the endothelial
barrier in the lungs and brown adipose tissue (Christoffersen et al., 2011; Christensen et al., 2016;
Christoffersen et al., 2018), but its effects on the BBB are largely unexplored. First, apoM-deficient
mice are less protected against neuroinflammation (Blaho et al., 2015). Second, conditional knock-
out of S1PR1 increases the BBB permeability towards small molecules (Yanagida et al., 2017), but
no data are available on how the BBB properties change with consistent S1PR1 expression, but dur-
ing reduced apoM levels.
Our objective was to determine the modulatory role of apoM for the BBB. We used two-photon
microscopy to image the brains of apoM-deficient (Apom-/-) mice in vivo in order to characterize
changes in BBB permeability in different categories of cerebral microvessels. Lack of apoM increased
the BBB permeability to small molecules without affecting the ultrastructural components of junc-
tional complexes and caused substantial increases in adsorptive transcytosis in pial and penetrating
arterioles, but not in venules and capillaries. Systemic administration of a selective S1PR1 agonist
SEW2871 promptly reversed the increased permeability for the paracellular route, whereas the nor-
mal rate of transcytosis was restored only in penetrating arterioles. We suggest that modulation of
the apoM signaling axis may be clinically relevant, but heterogeneous responses of distinct vessel
types to apoM shortage and S1PR1 agonist treatment should be taken into account in the develop-
ment of protective strategies in neurological conditions.
Results
Deficiency in apoM increases BBB permeability
To assess the BBB with all structural constituents we used two-photon fluorescence imaging in vivo
in transgenic apoM-deficient mice (Apom-/-) mice (Christoffersen et al., 2011), which in contrast to
other animal models, e.g. S1pr1iECKO (S1pr1 knock-out) mice (Yanagida et al., 2017), retain expres-
sion and function of S1PR1 (Christoffersen et al., 2011). Following preparative surgery (Figure 1a),
the brain was imaged in living anesthetized animals through an acute craniotomy over the somato-
sensory cortex (Figure 1b).
First, the integrity of the BBB was assessed after an i.v. bolus injection of sodium fluorescein
(NaFluo). NaFluo is a small (0.365 kDa), negatively charged hydrophilic molecule, which determines
its preferred route across the BBB via paracellular diffusion, and has been shown to be suitable for
characterizing the paracellular leak, independently from vesicular transport across the barrier
(Cheng et al., 2010; Hawkins and Egleton, 2006; Kozler and Pokorny´, 2003).
The fluorescence signal from blood-circulating fluorophore and brain parenchyma was simulta-
neously measured for 30 min in a series of Z-stacks of relatively large brain volume (750 mm x 750
mm x 114 mm) that contained pial and penetrating microvessels, and capillaries (Figure 1c). Each
Z-stack underwent dimensionality reduction, that is, maximum intensity projection along the Z
(depth) axis. The changes in fluorescence in brain parenchyma were not apparent on raw fluores-
cence data images (Figure 1c), therefore we chose to represent the data as relative increases of
fluorescence over the baseline (Figure 1d–e).
The morphology of the vasculature delineated by blood-circulating NaFluo did not differ between
WT and Apom-/- mice (Figure 1d). We detected a progressive accumulation of NaFluo in the brain
parenchyma in both WT and apoM-deficient mice. However, Apom-/- mice exhibited considerably
higher levels of fluorophore accumulation in the brain compared to WT mice already at 15 min after
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Figure 1. Two-photon imaging of paracellular permeability changes in Apom-/- mice. (a) Schematic of a mouse after preparative microsurgery for two-
photon imaging, with (b) craniotomy over the somatosensory cortex. (c) Three-dimensional reconstruction of the brain microvasculature from a single
Z-stack after i.v. injection of NaFluo. Each Z-stack corresponds to a single time point and underwent dimensionality reduction by maximum intensity
projection along the Z-axis (depth). (d) Relative fluorescence change over the baseline (first projected Z-stack in the recording). Contours delineate the
Figure 1 continued on next page
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injection, with a clear difference at the 30 min time-point (Figure 1d, Video 1). As apoM is the main
carrier for S1P in the blood stream and S1P bound to apoM primarily activates S1PR1 on the endo-
thelial cells (Prager et al., 2015; Murata et al., 2000), we tested whether the increase in BBB per-
meability due to the lack of apoM was a consequence of the S1PR1 hypostimulation. The Apom-/-
mice were i.p. injected 150 min prior to imaging with a selective S1PR1 agonist, SEW2871. Com-
pared to untreated Apom-/-, the SEW2871-treated Apom-/- mice exhibited decreased permeation of
NaFluo into the brain (Figure 1d, Video 1), suggesting that the S1PR1 agonist rescued the abnormal
Apom-/- BBB phenotype. This result indicates that the apoM deficiency impairs S1PR1 signaling to
the degree that causes increased BBB permeability. We next examined whether the BBB also exhib-
ited increased permeability towards other molecules of different sizes and chemical properties. Each
animal in the WT, Apom-/-, and Apom-/- SEW2871-treated group was injected at 30 min intervals
with fluorophores of decreasing molecular size, starting with 10 kDa FITC-dextran, followed by 0.643
kDa Alexa Fluor 488 and 0.365 kDa NaFluo (Figure 1e). After each injection, we imaged the same
brain volume over time, with subsequent dimensionality reduction of the Z-stacks. To compare ani-
mal groups, we measured the changes in fluorescence signal over time from ROIs placed in the brain
parenchyma and vasculature (n = 7 mice in each group), and accounted for systematic error in mea-
surement of consecutively injected fluorophores (see Methods section, Figure 1—figure supple-
ment 1).
For both tracer molecules, Alexa Fluor 488 and NaFluo, and in all animal groups, we detected
fluorescence increase over time in the parenchyma, and the effect was persistent without the signal
reaching saturation (Figure 1f). In contrast, there was no increase in brain fluorescence for FITC-dex-
tran (Figure 1e–f). To better characterize the fluorescence increase over time, we calculated the
area under the curve (AUC) of the signal traces, that is, the cumulative fluorescence increase for the
duration of 30 min after each fluorophore injection (Figure 1f–g). We observed no differences in
BBB permeability between WT and Apom-/- mice for 10 kDa FITC-dextran (WT 0.0086 ± 0.0056 min
vs. Apom-/- 0.033 ± 0.023 min, p=0.3068), but
Figure 1 continued
main cerebral microvasculature. Compared to WT, the Apom-/- animals had increased accumulation of NaFluo in the brain parenchyma over time,
which was ameliorated by treatment with S1PR1 agonist SEW2871. (e) Bolus injections of fluorophore were separated by 30 min time-lapse imaging
intervals. The panels show fluorescent molecule accumulation in the brain parenchyma for all tested fluorophores at 30 min post-injection. (f) Changes
in fluorescence intensity over time in the brain parenchyma and the blood circulation expressed as a fraction of the baseline. (g) Quantitative
assessment of the total effect 30 min post-injection by area under the curve (AUC) calculation. Left bar plot: increased paracellular permeability of the
BBB in Apom-/- mice towards sodium fluorescein (0.365 kDa) and Alexa Fluor488 (0.643 kDa), but not large molecule FITC-dextran (10 kDa). Right bar
plot: no differences in the signal decrease of blood-circulating fluorophores among all experimental groups. (h) The mean arterial blood pressure
during imaging was the same in all experimental groups. All data are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001.
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. Data analysis: (a) Brain parenchyma fluorescence traces from three consecutively injected fluorophores with an exponential curve
fit to the FITC-dx trace.
Video 1. Lack of apoM leads to a reversible increase in
BBB paracellular permeability. Accumulation of NaFluo
in brain parenchyma presented as fluorescence
increase relative to the baseline. Fluorophore injections
occurred 1 min before the first recorded imaging
plane.
https://elifesciences.org/articles/49405#video1
Video 2. WT mice BBB paracellular permeability
towards NaFluo, Alexa Fluor 488, and 10 kDa FITC-dx.
Accumulation of fluorophores in brain parenchyma
presented as fluorescence increase relative to the
baseline. For each time-lapse recording, the respective
fluorophore was injected 1 min before the first
recorded imaging plane.
https://elifesciences.org/articles/49405#video2
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the BBB in Apom-/- mice was significantly more permeable to small molecules, such as Alexa Fluor
488 (WT 0.90 ± 0.31 min vs. Apom-/- 2.43 ± 0.61 min, p<0.05) and NaFluo (WT 5.11 ± 1.3 min vs.
Apom-/- 27.5 ± 4.9 min, p<0.001) (Figure 1g, Videos 2–3).
Treatment of the Apom-/- mice with SEW2871 markedly reduced the leakage of both Alexa Fluor
488 and NaFluo compared to untreated Apom-/- mice (0.75 ± 0.38 vs. 2.43 ± 0.61 min, p<0.05; and
5.45 ± 1.6 min vs. 27.5 ± 4.9 min, p<0.01; Figure 1e–g, Videos 3–4). The reversal of the dysfunc-
tional BBB phenotype occurred relatively fast, and at 150 min post-treatment with SEW2871, the
BBB permeability was the same in Apom-/- and WT mice (p=0.6949 and p=0.8778 for Alexa Fluor
488 and NaFluo, respectively; Figure 1g). In addition we performed the same analysis on arbitrary
fluorescence units [a.u.], that is non-normalized data (Figure 1—figure supplement 1e–f) and the
results were in accord with relative fluorescence increases. We chose to report the data as relative
changes for the results to be more easily comparable between different imaging setups.
Importantly, the decrease in fluorescence signal in vessels (i.e., clearance of the respective fluoro-
phore from the blood circulation) did not differ between WT, Apom-/-and Apom-/- SEW2871-
treated mice for each respective fluorophore (Figure 1f–g). In addition, we found no differences in
mean arterial blood pressure between animal groups before (pre-imaging) or after the administra-
tion of all fluorophores (post-imaging) (Figure 1h). Thus, the increased fluorescence accumulation in
the brains of Apom-/- mice and reduced accumulation of fluorophores in the brains of SEW2871-
treated Apom-/- mice were not caused by different kinetics of a fluorophore clearance from the
blood stream or differences in blood pressure.
These results show that apoM shortage increases the BBB permeability towards small molecules
(~0.3–0.7 kDa), and that the effect can be reversed by S1PR1 stimulation.
Deficit in apoM signaling does not alter BBB tight junction
ultrastructure
Increases in the BBB permeability towards small molecules may be indicative of defective structural
elements that restrict paracellular diffusion across the BBB, e.g. junctional complexes (Davies, 2002;
Engelhardt et al., 2014; Salameh et al., 2016). Therefore, we next assessed the ultrastructure of
the BBB using transmission electron microscopy (TEM).
We analyzed brain microvessels (<6 mm) cross-sections from WT, Apom-/-, and SEW2871-treated
Apom-/- mice. In contrast to capillaries, large vessels were susceptible to perfusion-fixation artifacts
(non-uniform distortion of endothelium neighboring large tissue-devoid areas, i.e. vessel lumen),
which rendered pial and penetrating vessels not suitable for TEM quantitative assessment of the
BBB ultrastructure. In each vessel, we measured the thickness of the endothelium, basement mem-
brane (both n = 104 vessels; four mice in each group), tight junctional complexes, and the endothe-
lial cleft, the percentage coverage of endothelial cell contact sites by junctional complexes (all
n = 164, four mice in each group), and the endothelial cell area (n = 104 vessels, four mice in each
group) (Figure 2, Figure 2—figure supplement 1). The width, length, and coverage of junctional
complexes were the same for all three groups of mice (Figure 2a–b, Figure 2—figure supplement
1a), suggesting that the compromised BBB was
not caused by a structural defect of junctions,
and that the rescue effect of SEW2871 was not
mediated by alteration of the morphology of
these structural components. However, we
detected an ~ 10% increase in the thickness of
the endothelium in S1P-signaling-deficient mice
compared to controls (Apom-/- 0.078±0.0026 mm
vs. WT 0.071 ± 0.0025 mm; p<0.05) and the res-
cue group (Apom-/-+SEW2871 0.070 ± 0.0025
mm; p<0.05; Figure 2c). Notably, the stimulation
of S1PR1 in Apom-/- mice decreased the endo-
thelial cell area (5.80 ± 0.37 vs. 4.24 ± 0.23 mm2;
p<0.001), with a strong trend for the cell area in
Apom-/- to be larger than in WT mice
(5.80 ± 0.37 vs. 4.78 ± 0.24 mm2; p=0.068;
Figure 2d). These changes were relatively small,
Video 3. Increase in the BBB paracellular permeability
in Apom-/- mice towards NaFluo and Alexa Fluor 488,
but not 10 kDa FITC-dx. Accumulation of fluorophores
in brain parenchyma presented as fluorescence
increase relative to the baseline. For each time-lapse
recording, the respective fluorophore was injected 1
min before the first recorded imaging plane.
https://elifesciences.org/articles/49405#video3
Mathiesen Janiurek et al. eLife 2019;8:e49405. DOI: https://doi.org/10.7554/eLife.49405 5 of 22
Research article Neuroscience
and they are unlikely to disrupt BBB structural integrity to induce robust permeability increase for
small molecules. Altogether, our results suggest that the increased permeability observed in Apom-/-
mice is not mediated by ultrastructural changes at the level of the junctional complexes.
ApoM/S1PR1 signaling deficit increases transcellular transport
Next, we examined whether lack of apoM leads to increased transcytosis in the BBB. The animals
were injected with bovine serum albumin conjugated to Alexa 488 (BSA-Alexa 488) into the blood
stream to monitor vesicular transport across the endothelium (Knowland et al., 2014). Following
the injections, the animals were continuously imaged for 120 min in a hyperstack mode with subse-
quent dimensionality reduction (as in Figure 1c). In all animal groups, and as early as 30 min post-
injection, we detected BSA-Alexa 488-containing vesicles at the BBB interface (Figure 3). Compared
to WT animals, Apom-/- mice exhibited increased albumin in endothelial cells, indicating that vesicu-
lar transport was increased in the absence of apoM. Furthermore, the treatment of Apom-/- animals
with SEW2871 reversed the observed effect, suggesting that the same apoM-dependent mechanism
underlies the previously observed increase in permeability for small fluorescent tracers, as well as
elevated transcytosis.
We detected no signs of fibrinogen entry into the brain parenchyma; and similarly to S1PR1 con-
ditional KO mice (Yanagida et al., 2017), there were no differences in morphology of microglia/
macrophages and astrocytes between WT and Apom-/- mice, suggesting lack of gliosis upon expo-
sure to albumin (Figure 3—figure supplement 1). However, we detected in the brain parenchyma
the presence of cells that sequestered blood-borne albumin (Figure 3). To identify the cells, we per-
formed a series of immunohistochemical analysis on PFA-fixated brains of Apom-/- mice to
investigate for the colocalization of cell-internalized BSA-Alexa488 with the immunofluorescence sig-
nal from ionized calcium binding adaptor molecule 1 (Iba-1, microglia/macrophages marker); trans-
membrane protein 119 (TMEM119, microglia-specific marker); RM0029-11H3 (monoclonal antibody
against macrophage-specific epitope) and glial fibrillary acidic protein (GFAP, astroglia marker).
First, we ascertained that the fixation protocol did not quench the signal from BSA-Alexa488 (Fig-
ure 3—figure supplement 2a). The albumin sequestering cells were identified to be macrophages
based on the colocalization of BSA-Alexa488 –positive cells with Iba-1 (microglia/macrophages
marker), and further with monoclonal anti-macrophage antibody RM0029-11H3 signal (Figure 3—
figure supplement 2b). There was no colocalization of the BSA-Alexa488 signal with the microglia-
specific marker (TMEM119) and astroglia (GFAP) (Figure 3—figure supplement 2c). We found only
minor signs (single puncta) of BSA-Alexa488 uptake by other cell types (Figure 3—figure supple-
ment 2b–c).
S1P signaling deficit elevates transcytosis only in arterioles
Next, we assessed whether the increase in transcellular transport caused by the S1PR1-signaling
deficiency was the same for all vessel types. The number of vesicles was quantified over time for
each individual vessel type: pial arterioles, penetrating arterioles, capillaries, post-capillary venules,
ascending venules, and pial venules (n = 5 mice). The data are expressed as the vesicle surface den-
sity, expressed as the number of vesicles per square micrometer of vessel surface area (Figure 4a).
In all experimental groups, the distribution of BSA-Alexa 488-positive vesicles was dependent on
vessel type and diameter. At 120 min post-injection, the highest vesicle density in WT mice was
observed in capillaries and gradually decreased with vessel diameter, regardless of the vessel type
(i.e., arterioles or venules) (Figure 4a). In Apom-/- mice, the deficiency in S1PR1 signaling selectively
increased transcytosis in pial and penetrating arterioles, but not in venules and capillaries. The effect
was most pronounced in penetrating arterioles, where the vascular vesicle density in Apom-/- mice
was 10-fold higher than in WT mice (Apom-/- 0.30 ± 0.071 vs. WT 0.038 ± 0.009 vesicles/100 mm2;
p<0.01), and three times higher than for pial arterioles (Apom-/- 0.099±0.0023 vs. WT 0.035 ± 0.0011
vesicles/100 mm2; p<0.05; Figure 4b). The level of transcytosis did not change in Apom-/- mice in
the capillaries, venules, or pial veins (p=0.2306, p=0.3562, and p=0.9546, respectively).
Penetrating, but not pial arterioles respond to SEW 2871 treatment
S1PR1 stimulation with SEW2871 led to normalization of the transcellular transport of albumin in the
penetrating arterioles of Apom-/- mice to the level of WT controls (Apom-/-+SEW2871 0.68 ± 0.016
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vs. WT 0.038 ± 0.009 vesicles/100 mm2,
p=0.1156; Figure 4b). In contrast, SEW2871
treatment did not decrease transcytosis in pial
arterioles (Apom-/-+SEW2871 0.84 ± 0.017 vs.
Apom-/- 0.99±0.023 vesicles/100 mm2; p=0.4879),
and albumin transport was still significantly ele-
vated compared to WT mice (Apom-/-+SEW2871
0.84 ± 0.017 vs. WT 0.35 ± 0.011 vesicles/100
mm2; p<0.05). Lastly, we assessed the kinetics of
the vesicular density increase over time with
respect to each animal group and vessel type. In
all vessel types and animal experimental groups,
the increase in BSA-Alexa 488 vesicle surface
density was persistent and did not reach satura-
tion at 120 min, indicating that the results were
not obscured by overloading the transcellular
transport with BSA-Alexa 488 (Figure 4c).
These findings show that transcellular trans-
port is upregulated in apoM-deficient mice, and that there is not only heterogeneity in the vascula-
ture susceptibility towards increased permeability, but also towards which vessels can be rescued by
stimulation of the S1PR1 signaling pathway.
Discussion
Understanding the influence of blood-borne signaling molecules on brain endothelial cells is critical
for an understanding of the BBB function. We report that lack of apoM increased the BBB perme-
ability for small molecules without changes in size, structure, magnitude, or subcellular localization
of tight junction complexes. Furthermore, we report an up to 10–fold increase in adsorptive transcy-
tosis in the endothelial cells of pial and penetrating arterioles, but not in venules and capillaries.
Thus, ApoM modulates the flux of small and large molecules to different extents in different vascular
segments. Finally, the increased BBB permeability for small molecules and transcytosis-mediated
large proteins could be rescued by selective stimulation of the S1PR1. So far, the two-photon assess-
ments of the BBB in vivo are scarce. The presented data is first to show the heterogeneity of the
BBB responses to S1PR1 impairment and treatment in different vessel types, thus underlines the
necessity of studying the BBB in a living brain with respect to different functional and anatomical
regions of the microvascular tree. This may be of particular importance in clinical research as S1PR1
modulation is currently used in FDA-approved therapies in humans (Brinkmann et al., 2010).
From among the exogenous tracers typically used in BBB paracellular permeability studies, we
chose three molecules with different sizes, NaFluo and Alexa Fluor 488 that readily diffuse via the
BBB, and FITC-dextran that has low BBB permeability (Shi et al., 2014; Kutuzov et al., 2018).
The loss of BBB integrity in Apom-/- mice was observed for small tracer molecules < 0.7 kDa, but
no significant leak was observed for 10 kDa dextran, which is in accordance with previous findings in
S1PR1–knock-out mice (Yanagida et al., 2017). However, in contrast to Yanagida and colleagues
(Yanagida et al., 2017), we show that it is not the complete absence of brain endothelial S1PR1 sig-
naling, but a lack of a specific fraction of S1P circulating in the blood (i.e., apoM-bound S1P) is suffi-
cient to impair the BBB, and occurs despite the presence of active S1PR1 (Christoffersen et al.,
2011). Although we cannot exclude that some NaFluo molecules were entrapped in transport
vesicles during their formation at the luminal side of the endothelium, in our experiments we did not
detect any vesicular fraction of NaFluo, Alexa Fluor 488 and FITC-dx at the BBB. In contrast, albu-
min-conjugated Alexa 488 showed clear vesicular pattern, which is consistent with transcytosis
(De Bock et al., 2016; Minshall et al., 2000; Minshall et al., 2002). Furthermore, NaFluo is a strong
target for endothelium efflux pumps, that is multidrug resistance proteins (MRP) that sequester the
tracer back to the blood stream (Hawkins et al., 2007). Therefore, we consider that the incidental
transcytosis of NaFluo, Alexa Fluor 488 or FITC-dx had negligible contribution to fluorescence
increases, and the effect observed in the brain parenchyma occurred due to the increase in paracel-
lular permeability.
Video 4. Apom-/- SEW2781-treated mice exhibit
normal BBB paracellular permeability towards NaFluo,
Alexa Fluor 488, and 10 kDa FITC-dx. Accumulation of
fluorophores in brain parenchyma presented as
fluorescence increase relative to the baseline. For each
time-lapse recording, the respective fluorophore was
injected 1 min before the first recorded imaging plane.
https://elifesciences.org/articles/49405#video4
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The increased permeability along the paracellular pathway occurs most commonly in response to
severe damage (Farrell and Shivers, 1984; Houthoff et al., 1982; Lossinsky et al., 1995) and is
typically reported to be secondary to the ultrastructural abnormalities of junctional complexes, such
as truncated morphology during acute BBB breakdown, for example in stroke, sepsis, and brain
tumors (Davies, 2002; Engelhardt et al., 2014; Knowland et al., 2014); and in diabetes
(Salameh et al., 2016). S1P has been previously shown as an endothelial barrier-enhancing molecule
in the lungs (Schaphorst et al., 2003; Dudek and Garcia, 2001; Garcia et al., 2001) and recently, in
the brain (Yanagida et al., 2017; Swendeman et al., 2017). Our data ties apoM shortage-induced
increase in BBB permeability with S1PR1. The mechanisms of S1PR1-mediated protective effect are
not yet fully understood, but may be linked with Rho superfamily of small GTPases. Stimulation of
S1PR1 and S1PR2 activates preferentially Rac and Rho, respectively, whilst S1PR3 stimulation acti-
vates both GTPases (Xiong and Hla, 2014; Windh et al., 1999). Rac and Rho modulate cytoskeleton
dynamics in various cell types (Burridge and Wennerberg, 2004), including the formation and main-
tenance of a cortical actin ring that stabilizes intercellular junctions between adjoining endothelial
cells (Garcia et al., 2001; McVerry and Garcia, 2004). At physiological concentrations, S1P acti-
vates preferentially Rac via S1PR1 over Rho (Garcia et al., 2001; Shikata et al., 2003; Hla, 2003),
Figure 2. Small changes in endothelium cell morphology, but not junctional complexes, accompany increased BBB paracellular permeability in
Apom-/-mice. TEM ultrastructure assessment of the structural components of the BBB revealed no changes in the (a) width or (b) length of junctional
complexes, with (c) a small increase in endothelial thickness in Apom-/- mice compared to WT mice and a decrease in SEW2871-treated Apom-/- mice.
(d) A small decrease in endothelial cell area was observed upon SEW2871 treatment in Apom-/- mice. Data are presented as interquartile distributions
with median (horizontal line) and mean (plus sign). The box whiskers indicate 10–90% percentiles. *p<0.05, ***p<0.001.
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. Complementary BBB measurements by TEM.
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which causes a redistribution of proteins that facilitate cortical actin ring assembly, and consequently
tightening of the barrier (Garcia et al., 2001; Mehta et al., 2005). Inhibition of Rac downstream of
S1PR1 leads to actin depolymerization, formation of F-actin stress fibers and increased permeability
(Wo´jciak-Stothard et al., 2001; Singleton et al., 2005), and S1PR2 causes Rho activation that inhib-
its Rac (Dudek and Garcia, 2001; Hla, 2003). However, the formation and disassembly of actin corti-
cal ring affecting BBB permeability should not be simply viewed as Rac vs. Rho antagonism, as
inhibition of Rho, similarly to Rac, can reportedly also increase barrier permeability, although without
interrupting the actin ring assembly (Garcia et al., 2001; Etienne-Manneville and Hall, 2002). Our
quantitative TEM assessment shows that apoM deficiency did not induce changes in junctional com-
plexes ultrastructure. This suggests that the increase of the BBB permeability in Apom-/- mice was
Figure 3. Increase in BSA-Alexa 488 uptake indicates an increase in transcellular transport in Apom-/- mice. Two-photon assessment of albumin uptake
(green puncta) 60 and 120 min post i.v. injection of BSA-Alexa 488. Arrowheads indicate numerous puncta of BSA-Alexa 488 vesicles at the BBB
interface in Apom-/- mice but only sparse labeling in WT and SEW2871-treated animals. pa = pial arteriole; pe = penetrating arteriole; cap = capillaries;
pv = pial venule; av = ascending venule.
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. Increased BBB permeability in Apom-/- mice is not associated with fibrinogen invasion and gliosis.
Figure supplement 2. Uptake of BSA-Alexa488 in the Apom-/- brain parenchyma by macrophages.
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Figure 4. Heterogeneous susceptibility of different categories of brain microvessels to increased transcytosis in Apom-/- mice. (a) Scatter plot showing
the distribution of the surface vesicle densities of individual vessels plotted against respective vessel diameters 120 min post BSA-Alexa 488 injection.
The blue areas represent the morphological division into distinct vessel types. Data from capillaries were mirrored to preserve the order of vessel
diameter change in the continuous brain microvascular tree. (b) Quantitative analysis showed the increase in albumin uptake in Apom-/- mice that was
Figure 4 continued on next page
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either uncoupled from cortical actin ring remodeling, or that during S1PR1 hypostimulation and
ongoing S1PR2-mediated Rho inhibition of Rac, the activity of Rac was still sufficient to maintain the
elements of scaffolding complex of cortical actin ring that stabilize junctional complexes.
The small (~10%) increase in endothelium thickness in Apom-/- mice may be due to the impaired
S1PR1 -dependent formation and the maintenance of the cortical actin ring; and formation of actin
stress fibers facilitated by S1PR2 activation (Garcia et al., 2001; Mehta et al., 2005; Wo´jciak-
Stothard et al., 2001; Singleton et al., 2005). Indirectly, BBB permeability changes may be due to
osmotic imbalance and cell swelling, but it is uncertain whether this occurs in the brains of Apom-/-
mice. Lack of S1PR1 activation aggravates edema in acute brain and lung injury (Ito, 2019), but here
the system may not be challenged enough to induce osmotic swelling, as Apom-/- mice have no
signs of lung edema and exhibit normal microvasculature morphology (Christoffersen et al., 2011).
Other processes may also influence endothelium thickness, but their relevance in Apom-/- mice is yet
to be established. For example, S1PR1 activity counteracts vascular endothelial growth factor (VEGF)
-mediated endothelium contraction in angiogenesis (Gaengel et al., 2012), but whether S1PR1
hypostimulation affects VEGF signaling in the adult brain in Apom-/- mice is unknown. In addition,
impaired S1PR1 signaling activates neuroinflammatory factors (Blaho and Hla, 2014; Blaho et al.,
2015), and for example TNF-alpha has been shown to alter cytoskeleton and hyperplastic properties
of endothelial cells (Kang et al., 2008; Stroka and Aranda-Espinoza, 2011). Thus, it cannot be
excluded, that the changes in endothelium morphology result from both: direct effect of S1PR1
hypostimulation on endothelial cell, and indirect effects linked with impaired BBB-induced loss of
brain homeostasis.
Notably, a significant increase in paracellular permeability without apparent changes in junctional
complex morphology has been observed by others following osmotic shock (Farrell and Shivers,
1984) and in claudin-5-deficient mice (Nitta et al., 2003). The loss of BBB integrity in Apom-/- mice
appeared to be to a lesser extent than in acute pathology (e.g., traumatic brain injury or ischemic
stroke), as the BBB permeability towards 10 kDa dextran did not increase in Apom-/- mice
(Habgood et al., 2007; O¨zen et al., 2018). Yet, even with is morphology intact, the BBB with a per-
sistent increase in permeability may still contribute to brain pathology (Carvey et al., 2009).
Our in vivo results characterize apoM as a blood-borne molecule that can affect the BBB perme-
ability via S1PR1. In inflammatory conditions, elevated concentrations of blood-circulating thrombin
activate protease-activated receptor-1 (PAR1), and subsequently barrier-disruptive metalloprotei-
nases (Bogatcheva et al., 2002; Rempe et al., 2016). On the contrary, low thrombin concentrations
activate protein C (APC), a substrate for endothelial cell protein C receptor (EPCR), which alters
PAR1 signaling to promote the synthesis of S1P via Sphk-1, and facilitates barrier enhancement
(Riewald et al., 2002; Feistritzer and Riewald, 2005). In addition, APC has been shown to also
induce S1PR1 phosphorylation, which further promotes the S1PR1 signaling branch in the endothe-
lium (Lee et al., 2001). In line with our results in Apom-/- mice, the barrier enhancement by blood-
borne thrombin occurred via S1PR1, as silencing of S1PR1 but not e.g. S1PR3 abolished the APC-
mediated effect (Feistritzer and Riewald, 2005; Finigan et al., 2005). Except for apoM and throm-
bin, S1P signaling can be modulated by hyaluronic acid (HA). Depending on the form, i.e. high-
molecular weight-HA (HMW-HA) or low-molecular weight (LMW-HA), the complex promotes interac-
tion of a cell-surface glycoprotein CD44 isoforms with either S1PR1 or S1PR1/3, respectively
(Singleton et al., 2006). This leads to enhancement of the barrier function via S1PR1 or an increase
in BBB permeability via S1PR3 due to transactivation (i.e. phosphorylation) of respective receptors
by CD44 isoforms, independently of S1P levels (Singleton et al., 2006). This further corroborates
our findings on the regulation of S1P signaling by blood circulating molecules via preferential activa-
tion of specific S1P receptors.
However, the analogies should be made with caution, as the mechanistic insights come primarily
from in vitro barrier models or non-brain tissue, where endothelial barrier properties may differ from
Figure 4 continued
present only in the arterial part of the vascular tree and absent in capillaries and venules. Only penetrating arterioles responded to SEW2871 treatment.
Numbers in brackets are the number of vessels across five mice in each group. The data are presented as mean ± SEM. (c) Average traces showing the
kinetics of the vesicle density changes for WT, Apom-/-, and Apom-/- SEW2871 treated mice with respect to different vessel types. The data are
presented as mean ± SEM. *p<0.05, **p<0.01.
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the BBB in vivo. For example, Rac and Rho are known to elicit cell-type and subcellular localization-
specific effects (Burridge and Wennerberg, 2004; McVerry and Garcia, 2004; Donati and Bruni,
2006), and their intracellular pathways are cross-linked with numerous regulatory feedback loops,
including for example Rho inhibiting Rac and vice versa (Burridge and Wennerberg, 2004;
Sander et al., 1999). This adds to the complexity of interpretation of Apom knock-out effects on
the BBB and is currently an active area in research.
The hypostimulation of S1PR1 in Apom-/- mice is likely to shift the signaling equilibrium towards
cellular pathways that promote activation of Rho (via S1PR2) over Rac (via S1PR1), and the effects of
increased BBB permeability are likely to be the net outcome of the failure in homeostatic interplay
between receptor-dependent branches of S1P signaling, rather than simply a decrease in Rac activ-
ity. Consequently, the observed impairment of the BBB cannot simply be linked to a reduction in the
amount of circulating S1P, but more specifically to the lack of apoM-bound S1P in favor of albumin-
bound S1P in the blood. This notion is further supported by the result of the selective stimulation of
S1PR1, which restored the BBB permeability in Apom-/- mice to the level of healthy controls.
Given that inhibition of S1PR2 tightens the endothelial barrier in lungs by facilitating cortical actin
ring assembly and stabilization of tight junctions (Sanchez et al., 2007), and in the brain supports
the BBB functional integrity (Kim et al., 2015; Cao et al., 2019), it is plausible that S1PR2 stimula-
tion may alleviate BBB phenotype in Apom-/- mice. It should be noted, however, that S1PR1 expres-
sion in the endothelium is higher in the arterial branch of cerebral vasculature compared to venules,
whereas S1PR2 expression is higher in venules than in arterioles (Vanlandewijck et al., 2018). It may
lead, similar as in SEW2871 treatment, to region-specific effects, where the BBB responses to S1PR2
modulation may differ between distinct types of cerebral microvessels.
Though paracellular permeability restriction is typically viewed as the main functional constituent
of the BBB, the low prevalence of transcytosis is equally important for preservation of the brain
microenvironment (Knowland et al., 2014; Habgood et al., 2007; Hashizume and Black, 2002;
Krueger et al., 2013). Recently, Mfsd2a was identified as a critical protein in the suppression of
transcytosis. Similar to Apom-/-, a lack of Mfsd2a leads to an increase in vesicular transport across
the endothelium that compromises the BBB without structurally opening the paracellular route (Ben-
Zvi et al., 2014) or changing junctional protein composition (Yang et al., 2017). Furthermore, the
increase in BBB permeability can occur via both the transcellular and paracellular routes, but at dif-
ferent time points; e.g. the increase in transcytosis rate can precede paracellular leakage in stroke
(Knowland et al., 2014), and selective dysregulation of the transcellular pathway can occur while
the tight junctions are preserved (Krueger et al., 2013). Thus, the intact morphology of junctional
complexes, as shown here, is not necessarily indicative of preserved BBB properties.
Noteworthy, the lack of apoM-S1P lead to an increased rate of transcytosis, though only in pial
and penetrating arterioles. The susceptibility of the arterial branch of the microvasculature to apoM
shortage may be linked to preferential expression of S1PR1 and APC in pial and penetrating arterio-
les (Vanlandewijck et al., 2018), thus possibly high reliance in these vessel types on S1PR1 signaling
in the maintenance of the BBB. It is unclear, however, why penetrating, but not pial arterioles
responded to SEW2871, but anatomical differences may be of importance. For example, S1P signal-
ing promotes the formation of the glycocalyx, which limits the diffusion of hydrophilic and negatively
charged substances, and supports the barrier function (Zhang et al., 2016). Glycocalyx in pial arte-
rioles is estimated to be thicker compared to the penetrating arterioles (Yoon et al., 2017), but it is
unknown how S1PR1 hypostimulation affects distribution and coverage of glycocalyx layer in
Apom-/- mice. In addition, the reconstitution of barrier function may have a different time course in
pial and penetrating arterioles. Lastly, in contrast to bolus SEW2871 injection, a sustained stimula-
tion of S1PR1 may be needed to restore BBB function in pial arterioles during ongoing apoM deficit.
High-density lipoprotein (HDL) particles are heterogeneous in size and content of apolipoproteins
and lipids. In humans, HDL plasma concentrations correlate with reduced susceptibility to cerebro-
and cardiovascular diseases (Rader and Tall, 2012; Hovingh et al., 2015; Fellows et al., 2015), and
approximately 5% of HDL contains apoM (Xu and Dahlba¨ck, 1999; Christoffersen et al., 2006).
The beneficial effects of HDL can be, in part, explained by HDL association to apoM/S1P. We show
that lack of apoM increases the flux of small molecules across the BBB, similar to previous findings
investigating the permeability in lung and adipose tissue (Christoffersen et al., 2011;
Christensen et al., 2016; Christoffersen et al., 2018). Stressing the system even further, lack of
apoM increases the susceptibility to neuroinflammation (Blaho et al., 2015; Galvani et al., 2015).
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Mainly this has been interpreted as effects caused by blood-circulating apoM/S1P complex. How-
ever, a recent study suggested that porcine brain endothelial cells express and secrete apoM into
the brain parenchyma (Kober et al., 2017). This has not been reported in other species but could
also play a role in the increased permeability observed in the present study. Except S1P, apoM can
potentially bind other ligands, for example retinoic acid (Ahnstro¨m et al., 2007) or oxidized phos-
pholipids (Elsøe et al., 2012). Lack of apoM would increase free oxidized phospholipid content,
which potentially can also affect the BBB (Singleton et al., 2009). However, reversing the BBB phe-
notype by SEW2871 suggests that the observed effects are primarily mediated via S1PR1 rather
than for example oxidized phospholipids. Noteworthy, with the absence of apoM, S1P may still asso-
ciate to HDL. A recent study showed that in mice lacking expression of both, apoM and albumin,
S1P binds to HDL via novel S1P binding protein apoA4 (Obinata et al., 2019). This may potentially
constitute a compensatory mechanism in Apom-/- mice, but whether HDL/apoA4/S1P complex also
plays a role in maintaining the BBB is unknown and will need further investigations.
Two-photon imaging allows studying the endothelial barrier in the living brain with all its struc-
tural and functional constituents, including blood flow, and at the resolution of single microvessels.
However, like any imaging approach, it has also limitations that apply to our study. In contrast to
transcellular vesicular transport, the fast diffusion of NaFluo in the brain parenchyma made it not fea-
sible to analyze for differences in paracellular permeability increase between distinct vessel types in
Apom-/- mice. Regarding the transcellular permeability assessment, we have only investigated the
transcytosis of albumin, which represents a fraction of receptor-mediated transcellular pathways.
Lastly, the surgical procedures might also affect the brain physiology, however in our previous works,
we observed no significant effects of cranial window preparation and imaging on the neurovascular
coupling, neuronal and astrocytic calcium transients, electrophysiological activity and cell morphol-
ogy, suggesting lack of effects on the brain that could significantly affect the BBB function
(Kutuzov et al., 2018; Kucharz and Lauritzen, 2018; Hall et al., 2014). Instead of acute craniot-
omy, further studies may employ chronic window imaging to address changes in BBB permeability in
Apom-/- mice over a longer time.
In summary, apoM is critical for maintaining low paracellular and transcellular permeability at the
BBB. The BBB is heterogeneous in the susceptibility towards apoM shortage and in the potential for
rescue mediated by the S1PR1 signaling pathway. The pronounced increase in transcytosis in
Apom-/- mice stresses the importance of considering the development of protective strategies for
this pathway to regulate the immediate microenvironment of brain cells and reduce secondary neural
damage in both acute and chronic neurological conditions.
Materials and methods
Animals
All animal procedures were approved by the Danish National Ethics Committee and were in appli-
ance with the ARRIVE guidelines. We used 14 to 20 week-old (22–28 g) female transgenic C57bl/6
apoM-deficient mice (Apom-/-) (Christoffersen et al., 2011), and age- and gender-matched wild-
type (WT) mice as the control group.
Anesthesia
Anesthesia was induced by a single bolus intraperitoneal (i.p.) xylazine (10 mg/kg body weight [BW])
and ketamine (60 mg/kg BW) injection. During all steps of the surgical preparation, the anesthesia
was maintained by i.p. injections of ketamine (30 mg/kg BW) at 25 min intervals. Thirty minutes
before imaging, the anesthesia was changed to continuous intravenous (i.v.) infusion of alpha-chloral-
ose (50 mg/hour/g BW).
Animal preparation for two-photon imaging
Animals were operated on as described previously (Kucharz and Lauritzen, 2018). Briefly, a trache-
otomy was performed for mechanical respiration (MiniVent Type 845, Harvard Apparatus) and to
monitor exhaled CO2 (MicroCapstar End-tidal CO2 Analyzer, CWE). Two catheters were inserted:
the first into the left femoral artery to monitor arterial blood pressure (Pressure Monitor BP-1, World
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Precision Instruments) and inject compounds, and the second into the femoral vein for infusion of
the anesthetic.
Next, a craniotomy was performed. The exposed skull was attached to a custom-made metal
head bar with cyanoacrylate gel (Loctite Adhesives) and mounted onto the microscope imaging
stage insert. The opening was made using a diamond dental drill (at 7000 rpm) over the somatosen-
sory cortex (4 mm diameter; coordinates: 3 mm lateral, 0.5 mm posterior to bregma). During the
procedure, the craniotomy and drill were cooled to room temperature repeatedly with artificial cere-
brospinal fluid (aCSF; in mM: NaCl 120, KCl 2.8, Na2HPO4 1, MgCl2 0.876, NaHCO3 22, CaCl2 1.45,
glucose 2.55, at 37˚C, pH = 7.4) to prevent brain damage from excessive heating of the drill. The
dura was removed and a drop of 0.75% agarose (type III-A, Sigma-Aldrich) applied onto the craniot-
omy. The opening was then secured with an imaging coverslip (Menzel-Gla¨ser) and kept under aCSF
to preserve humidity. To ensure physiological O2 and CO2 blood concentrations, prior to imaging, a
50 ml blood sample was collected via the arterial catheter (ABL blood gas analyzer, Radiometer), and
the respiration rate and volume adjusted if necessary.
Fluorescent probes
FITC-dextran (MW 10 kDa, 0.5%, 0.05 ml, Sigma-Aldrich), Alexa Fluor 488 (MW 0.643 kDa, 0.025%,
0.04 ml, Invitrogen), and sodium fluorescein (NaFluo, MW 0.365 kDa, 1%, 0.04 ml, Sigma-Aldrich)
were each dissolved in sterile saline and administered via the arterial femoral catheter as single bolus
injections. Bovine serum albumin (BSA) Alexa Fluor 488-conjugate (BSA-Alexa 488, Invitrogen) was
administered via the arterial femoral catheter as a single bolus injection (0.05 ml 1%), together with
TRITC-dextran (MW 65 kDa, 0.05 ml 1%, Sigma-Aldrich) for delineation of the vasculature and to
ascertain that vessels were not damaged following the cranial window microsurgery that could lead
to false-positive results.
Two-photon imaging setup
Two-photon imaging was performed using an SP5 upright laser scanning microscope (Leica Micro-
systems) equipped with a MaiTai Ti:Sapphire laser (Millennia Pro, Spectra-Physics) using the 20  1.0
NA water-immersion objective. The emitted light was split by a FITC/TRITC filter and collected by
separate multi-alkali detectors after 525–560 nm and 560–625 nm bandpass filters (Leica
Microsystems).
Monitoring paracellular permeability
The excitation wavelength for FITC-dextran, Alexa Fluor 488, and NaFluo was 850 nm (14 mWatt
output power at the sample). Data were collected as 16-bit image hyperstacks at 512  512 pixel
resolution (775 mm x 775 mm) in bidirectional scanning mode with a Z-step size of 5 mm (depth
span = 114 mm) and 1 min time interval between Z-stacks. The total recording time for each fluoro-
phore was 30 min. The recordings were exported to ImageJ (NIH, version 1.48u4) and Z-projected
using maximal signal intensity projection. Regions of interest (ROIs) were chosen throughout the
brain parenchyma at all locations deprived of vasculature for the measurement of fluorescent inten-
sity. An increase in fluorescent intensity over the baseline (first projected Z-stack in the time-lapse
recording) in the parenchyma indicated crossing of the blood-circulating fluorophore into the brain.
FITC-dextran, Alexa Fluor 488, and NaFluo were consecutively injected in 30 min intervals into
the same animal. We did not wait for the fluorophores clearance, as the time of bloodstream clear-
ance differs between fluorophores, and varies between animals. Consequently, this could obscure
characterization of the biological effects of SEW2871 on the BBB, as the assessment of permeability
in each mouse for each respective tracer would be performed at different time after the drug admin-
istration. SEW2871 has a relatively short half-time in the blood plasma with its biological effects
peaking at 1 hr, and returning to baseline 4.5 hr after administration (as determined by, for example
Akt phosphorylation)(Jo et al., 2005). Instead, we chose to standardize the time of imaging after
SEW2871 injection, that is FITC-dx, Alexa Fluor 488, and NaFluo were always imaged 2.5 hr, 3 hr,
3.5 hr after SEW2871 administration, respectively. In our calculations we estimated the contribution
of a preceding fluorescence accumulation to a subsequent fluorophore(s) signal measurement. For
each mouse, we subtracted the constant autofluorescence background from FITC-dx, Alexa Fluor
488, and NaFluo trace and performed an exponential fit to the FITC-dx trace, and the fit was
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extrapolated to subsequently imaged Alexa Fluor 488 and NaFluo (Figure 1—figure supplement
1a). We chose the exponential fit to account for the largest systematic error in our experiment,
that is the largest theoretical contribution of a preceding tracer to a subsequent tracer signal. The
fluorescence is additive, therefore we corrected Alexa Fluor 488 and NaFluo traces by subtracting
FITC-dx extrapolated fit values (Figure 1—figure supplement 1a) and effectively, uncoupled FITC-
dx kinetics from Alexa Fluor 488 and NaFluo. Next, to the corrected trace of Alexa Fluor 488 we per-
formed an exponential fit and extrapolated it to the time of NaFluo imaging. Similarly as before, we
subtracted Alexa Fluor 488 extrapolated fit from NaFluo trace (Figure 1—figure supplement 1b).
The same approach, but with exponential decay fit, was used to account for the baseline fluores-
cence changes in the bloodstream (Figure 1—figure supplement 1c–d).
Monitoring transcellular transport
The animals were injected intravenously with BSA-Alexa 488. The excitation wavelength was 870 nm
(17 mWatt output power at the sample). Data were collected as 16-bit hyperstacks at 2048  2048
pixel resolution (386.66 mm x 386.66 mm) in bidirectional scanning mode and triple frame averaging
with a Z-step size of 2.50 mm, depth span 144 mm, and 7.5 min interval between Z-stacks for a total
recording time of 120 min. The data were exported to ImageJ and Z-projected using maximal signal
intensity projection. Based on morphology and location, the vessels were classified as pial arterioles
or venules, penetrating arterioles, post-capillary venules, ascending venules, or capillaries. To deter-
mine the vesicle surface density, the vessel surface area was calculated based on the diameter and
length of the vessel from which the BSA-Alexa 488 signal was counted.
Transmission electron microscopy
The mice were anesthetized with bolus i.p. injections of xylazine (10 mg/kg BW) and ketamine (60
mg/kg BW), then perfused with Karnovsky fixation (2% glutaraldehyde and 4% paraformaldehyde).
Brains were harvested and the cortex cut into 1 mm cubes and left for further fixation in 2% glutaral-
dehyde in 0.05 M phosphate buffer for 7 days. For transmission electron microscopy (TEM) staining,
the samples were washed three times for 15–20 min in 0.12 M cacodylate buffer, followed by post-
fixation in 1% osmium tetroxide (OsO4) and 0.05 M (1.5%) potassium ferricyanide (K3FeCn6) in 0.12
M cacodylate buffer for 1 hr at room temperature (RT). Next, the samples were washed three times
for 15–20 min in ddH2O and then dehydrated in an ethanol gradient (70%, 96%, and 3  15 min in
absolute ethanol). Infiltration was performed with propylene oxide twice for 15 min, followed by
incubation for 20–40 min in a resin epon/propylene oxide (Bie and Berntsen) gradient (1:3, 1:1, 3:1)
and pure resin for 2 hr. Samples were embedded in resin at 60˚C for 24 hr. Sections were cut at a
thickness of 70 nm (Leica EM UC7), placed on copper grids (Leica), and stained with lead citrate
(Leica Ultrostain II, Leica Microsystems) for 3 min and uranyl acetate (Leica Ultrostain I, Leica Micro-
systems) for 10 min using an automatic contrasting system (Leica EM AC20, Leica Microsystems).
Imaging was performed using a CM100 transmission electron microscope (Phillips/FEI, ITEM soft-
ware) at 9700x – 17500x and 46000-60000x magnification. Two samples from each mouse were
imaged, and 20–30 capillaries from each sample were chosen randomly. ImageJ was used for the
measurement of BBB morphology.
Immunohistochemistry
The isoflurane-anesthetized mice were transcardially perfused at the rate of 10 ml/min for 1 min with
saline and then for 7 min with ice-cold 4% paraformaldehyde (PFA). The brains were placed in 4%
PFA for 24 hr at 4˚C for post-fixation, then in 25% sucrose in PBS for ~ 24 hr at 4˚C. The brains were
frozen in dry ice and cut into a series of 35 mm thick coronal sections (Microm HM450 microtome,
Thermo Fisher Scientific).
For fibrinogen staining, we performed antigen retrieval in Tris/EDTA buffer (pH 9.0) for 30 min at
80˚C, with a quenching step in 3% H2O2 and 10% methanol in Tris-buffered saline (TBS) for 20 min.
The sections were washed 3x in TBS and pre-incubated for 1 hr at the RT with 5% normal goat serum
in 0.25% triton-X in TBS (TBS-T). Subsequently, the sections were incubated o/n at RT with anti-
fibrinogen primary antibody (1:2000, ab227063, Abcam) in 5% normal goat serum TBS-T solution.
Following that, the tissue sections were rinsed 3  10 min in TBS-T and incubated in 1% BSA TBS-T
with biotinylated secondary goat-anti-rabbit antibody (1:200; Vector Laboratories Inc). Next, the
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sections were washed 3x in TBS-T for 10 min, then incubated with an avidin-biotin-peroxidase com-
plex solution for 1 hr at RT, and washed again 3  10 min with TBS-T. The staining was visualized
using 3,3’-diaminobenzidine (DAB) and 0.01% H2O2 according to manufacturer’s instructions. Lastly,
the sections were mounted on chromatin-gelatin coated glass slides, stained in 0.1% cresyl violet
(CV) solution for 3 min, dehydrated in increasing alcohol solutions (70%, 95%, 100%), cleared in
xylene and using a DPX mountant (Sigma-Aldrich), the slides were coverslipped for imaging.
Heat-mediated antigen retrieval was performed on the free-floating brain sections using sodium
citrate buffer (pH6) for anti-TMEM119 staining, and EDTA buffer (pH 8.0) at 80˚C for 30 min for anti-
macrophage staining (RM0029-11H3). The sections were rinsed 3  10 min in 0.1 M potassium phos-
phate-buffered saline (KPBS), then placed for 1 hr in KPBS 0.05% Triton-X (KPBS-T) containing 5%
normal goat serum. Next, the sections were incubated o/n at RT with primary antibodies in 5% nor-
mal goat serum solution in KPBS-T. The primary antibodies used were: anti-macrophage (1:200;
RM0029-11H3; rabbit; Abcam cat# ab56297), recombinant anti-TMEM119 (1:200; rabbit; Abcam
cat# ab209064), anti-Iba1 (1:1000; rabbit; Wako cat# 019–19741) and anti-GFAP (1:500; rabbit;
DAKO cat# Z033429-2). The sections were rinsed 3  10 min in KPBS-T and then incubated with
Alexa647-conjugated secondary antibody (1:200, goat-anti-rabbit, Invitrogen) in KPBS-T for 2 hr at
RT. Following that, the sections were rinsed 3x for 10 min with KPBS, and incubated with DAPI (40,6-
diamidino-2-phenylindole) solution (Thermo Fisher Scientific) for 10 min. Lastly, the sections were
mounted on gelatin-coated slides and secured with coverslips using an anti-fading medium (Slow-
Fade Diamond Antifade Mountant, S36963, Thermo Fisher Scientific) for fluorescence confocal
imaging.
Confocal imaging
Confocal imaging was performed using DMi8 inverted fluorescence microscope (Leica Microsystems)
equipped with a 40  1.3 NA oil-immersion objective. DAPI, BSA-Alexa488, and Alexa647 were
excited with 405 nm, 488 nm, and 638 nm laser diodes, respectively. The imaging was performed in
sequential mode (each channel separately), to avoid fluorescence bleed-through between the chan-
nels. The emitted light was collected by a hybrid detector after: 410–450 nm (for DAPI), 510–550 nm
(for BSA-Alexa488), and 650–750 nm (for Alexa647–conjugated antibodies) bandpass.
Bright-field imaging of fibrinogen/cresyl violet staining was performed using BX53 upright trans-
mitted light microscope (Olympus) equipped with a 60  1.4 NA oil-immersion objective.
All images were exported to ImageJ (NIH, version 1.48u4) for further analysis. For comparisons
between WT and Apom-/- mice, the images were collected using the same microscope settings, and
Z-projected using maximal signal intensity projection from an equally thick section (=10 mm). The WT
vs. Apom-/- mice imaging data on the figures are presented in the fluorescence signal intensity scale.
Drug administration
SEW2871 (Sigma-Aldrich) was diluted in PBS (to 0.1 mg/ml in 1% DMSO) and administered as a sin-
gle i.p. bolus injection (10 mg/g BW) 150 min prior to two-photon imaging or perfusion fixation.
Statistical analysis
Statistical analysis was performed using Prism 7 (v7.0b, Graphpad) and R software (v3.5.1). The data
were tested for normal distribution with Pearson’s normality test and either an unpaired two-tailed
Student’s t-test with Welch’s correction (normally distributed data) or Mann-Whitney test (non-nor-
mally distributed data) was used. The TEM data underwent logarithmic transformation and was eval-
uated using one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test.
The sample size has been selected based on our previous experiments using two-photon in vivo
microscopy (Kucharz and Lauritzen, 2018), in vivo electrophysiology (Kucharz et al., 2017) and
TEM (Christoffersen et al., 2011). The data consisted only of biological replicates, the number of
independent biological replicates (N) is provided in the results section and/or on figures. All analyses
were performed in randomized order, with TEM analysis performed blinded to experimental condi-
tions. No animals or data outliers have been excluded from analysis.
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